Clinical Trial Search

Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours

Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…

Primary: Time to Recovery — 66.0; 68.6 Hours — p==0.2524

Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours

Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003

Primary: Duration of Diarrhea — 2; 2 days — p=0.43

Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88

Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…

Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…

Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients

Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Reduction in Frequency of Defecation to 3 Times Per Day — 118; 24 Participants

Primary: Number (or Percentage) of Infants in Each Study Arm Who Test Positive for Fecal Rotavirus Vaccine-strain Virus Shedding Post-vaccination — 63; 55 Participants

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants

Primary: Time to Last Unformed Stool (TLUS) — 37.4; 21.; 68; 46 TLUS (hours)

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants

Primary: Number of Participants That Were Successfully Rehydrated — 57; 49 Participants — p=0.28

Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001

Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours

Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day

Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants

Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants

Primary: Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days) — 44.4; 55.6 Percentage of…

Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78